Mylan

Chutes & Ladders-Viatris appoints Pfizer CFO Narula to C-suite

1 month ago   |   Fierce Biotech

Pfizer, Mylan vets move over to generics merger Viatris; Spark CMO Reape steps down; Eloxx cuts CEO Ward in shakeup.
Read more ...

Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch

Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch

1 month ago   |   Xconomy

A contraceptive patch developed by Agile Therapeutics was awarded FDA approval late Friday, clearing the way for a new birth control option to reach the market. The Agile...
Read more ...

Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More

Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More

4 monthes ago   |   Xconomy

Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention. It's still...
Read more ...

Drug Pricing: Innovation, Investment, and the Public Good

Drug Pricing: Innovation, Investment, and the Public Good

6 monthes ago   |   Xconomy

The US biotech and life sciences industry has a long and proud history of driving medical innovations that have improved healthcare outcomes across a wide range of diseases and...
Read more ...

Chutes & Ladders-Mylan CEO Bresch to exit company after Upjohn merger

8 monthes ago   |   Fierce Biotech

Mylan CEO Bresch set to retire after merger with Pfizer spinoff Upjohn; Adaptimmune CSO leaving to "pursue other opportunities"; Verastem pegs Stuglik as next head honcho.
Read more ...

Bio Roundup: Pfizer's Future, CRISPR in Patients, Drug Imports & More

Bio Roundup: Pfizer's Future, CRISPR in Patients, Drug Imports & More

8 monthes ago   |   Xconomy

Acquisitions made Pfizer what it is today: the world's biggest drug maker measured by revenue. But as the company maps its future, CEO Albert Bourla is breaking some of that...
Read more ...

Upjohn & Mylan to Merge, Freeing Pfizer to Focus on Biopharma R&D

Upjohn & Mylan to Merge, Freeing Pfizer to Focus on Biopharma R&D

8 monthes ago   |   Xconomy

Pfizer became the world's biggest drug maker by revenue through acquisitions that diversified its portfolio. Now it's spinning out its off-patent drug division and charting a...
Read more ...

Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience

Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience

11 monthes ago   |   Xconomy

A month after the failure of its once-promising Alzheimer's disease drug aducanumab shattered its share price, Biogen is trying to pick up the pieces. Biogen hosted a...
Read more ...

Acorda Gets FDA Nod for New Parkinson's Drug, But Rival Looms

Acorda Gets FDA Nod for New Parkinson's Drug, But Rival Looms

One year ago   |   Xconomy

The FDA late Friday approved a new treatment meant to help Parkinson's disease patients cope with “off” episodes, when their medications stop working. The drug, Inbrija , from...
Read more ...

Bio Roundup: EpiPen Shortage, Bluebird's Bet, Biotech IPOs & More

Bio Roundup: EpiPen Shortage, Bluebird's Bet, Biotech IPOs & More

One year ago   |   Xconomy

It's back-to-school season and that means it's time to load up on school supplies. For many students and schools, one crucial item is in high demand but hard to come by: the...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the... Read more ...

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is... Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a... Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic... Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Methylation-driven model for analysis of dinucleotide evolution in genomes

CpGs, the major methylation sites in vertebrate genomes, exhibit a high mutation rate from the methylated form of CpG to TpG/CpA and, therefore, influence the evolution of... Read more ...